Private psychedelics biotech company Gilgamesh Pharmaceuticals is currently developing a diverse portfolio of novel, potentially first-in-class compounds targeting mechanisms with demonstrated clinical efficacy, onset duration or prolonged treatment duration, for the treatment of psychiatric conditions.
Gilgamesh’s work focuses on the central nervous system (CNS). As such, the company is developing a pipeline of novel agents that retain or improve on the therapeutic effects of prototypical psychoactive substances—like psilocybin, LSD, ketamine and MDMA—while enhancing their safety and efficacy profile.
